A Review of the Economics of Treating Clostridium difficile Infection

@article{Mergenhagen2014ARO,
  title={A Review of the Economics of Treating Clostridium difficile Infection},
  author={Kari A. Mergenhagen and Amy L Wojciechowski and Joseph A. Paladino},
  journal={PharmacoEconomics},
  year={2014},
  volume={32},
  pages={639-650}
}
Clostridium difficile infection (CDI) is a costly result of antibiotic use, responsible for an estimated 14,000 deaths annually in the USA according to the Centers for Disease Control and Prevention. Annual costs attributable to CDI are in excess of $US1 billion. This review summarizes appropriate utilization of prevention and treatment methods for CDI that have the potential to reduce the economic and humanistic costs of the disease. Some cost-effective strategies to prevent CDI include… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 98 references

Cost-effectiveness of fidaxomicin for Clostridium difficile treatment

  • MS Simon
  • Clin Infect Dis. 2014;58(4):603
  • 2014

Similar Papers

Loading similar papers…